Constructive Bio appoints biopharma leader Jim Weissman to its Board of Directors
Constructive Bio, a leading synthetic biology company, today announces the appointment of Jim Weissman to its Board of Directors.
Constructive Bio Partners with RxCelerate to Advance ncAA-Containing Biologics Through Drug Design and Development
Constructive Bio and RxCelerate have partnered to combine programmable biology and ncAA-enabled protein engineering with drug design and development capabilities,…
Constructive Bio Licences tRNA Display Technology for Incorporating Non-Canonical Amino Acids into Peptides and Proteins
Constructive Bio has secured an exclusive licence for tRNA display technology, enabling directed integration of non-canonical amino acids (ncAAs) and…
Constructive Bio Raises $58M Series A to Scale Fermentation-Based Peptide Manufacturing with Non-Canonical Amino Acids
Constructive Bio secured $58 million in Series A financing, bringing total funding to $75 million, to scale its BioForge fermentation…
